CN104208117A - Plant extract compound product with function of maintaining liver - Google Patents
Plant extract compound product with function of maintaining liver Download PDFInfo
- Publication number
- CN104208117A CN104208117A CN201410470256.9A CN201410470256A CN104208117A CN 104208117 A CN104208117 A CN 104208117A CN 201410470256 A CN201410470256 A CN 201410470256A CN 104208117 A CN104208117 A CN 104208117A
- Authority
- CN
- China
- Prior art keywords
- liver
- astaxanthin
- protecting function
- product
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 239000000419 plant extract Substances 0.000 title claims abstract description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 36
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 26
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 26
- 239000001168 astaxanthin Substances 0.000 claims abstract description 26
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 26
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 26
- 239000004148 curcumin Substances 0.000 claims abstract description 18
- 229940109262 curcumin Drugs 0.000 claims abstract description 18
- 235000012754 curcumin Nutrition 0.000 claims abstract description 18
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims description 42
- 241000196324 Embryophyta Species 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 241000208838 Asteraceae Species 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 17
- 206010016654 Fibrosis Diseases 0.000 abstract description 2
- 230000004761 fibrosis Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000245665 Taraxacum Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- -1 Superoxide anion free radical Chemical class 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 7
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 7
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 7
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007968 orange flavor Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 2
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000168517 Haematococcus lacustris Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 108010065394 aminopherase Proteins 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a plant extract compound product with the function of maintaining a liver. The plant extract compound product is prepared from the following components including astaxanthin, dandelion and curcumin with the weight ratio of 1:(10-30):(10-40). The plant extract compound product is capable of providing the efficacy of detoxication, oxidation, inflammation, fibrosis and cancer resistance and the like for the liver and providing comprehensive protection for the liver, is strong in functions and is little in toxicity.
Description
Technical field
The present invention relates to functional plants compound extract, particularly a kind of have the novel liver-protection health-care product safeguarding liver function.
Background technology
One of Main Function of liver is " removing toxic substances ".So-called " removing toxic substances " refers to that liver can wrap up the chemical substance be absorbed in daily life in body, and discharge human body, this is the critical function of liver.
Human body all by breathing, diet or can be smoked and drink every day, absorbs all harmful substances such as virus or medicine.Liver can be responsible for detoxifying to these harmful substances.But, once harmful substance quantity has exceeded the disposal ability of liver, liver function will be caused low, caused health disease.Therefore, the function of detoxification improving liver is very important for maintenance health.
The astaxanthin that the present invention relates to comes from Haematocoocus Pluvialls extract.It is reported, astaxanthin is the strongest antioxidant found so far, has remarkable liver detoxification function.Alcoholic hepatitis, chronic viral hepatitis produces excessive free radical in the course of disease.These Superoxide anion free radical result in serious liver injury just.The anti-oxidation characteristics that astaxanthin is stronger contributes to suppressing free radical, reduces its oxidative damage to liver.Astaxanthin In Haematococcus Pluvialis product is on the impact of human health, compare with other 26 kinds famous anti-inflammatory drugs, result show, the health status taking astaxanthin patient improves 85%, astaxanthin and 92% anti-inflammatory drug have equal effect or effect better.
The Herba Taraxaci that the present invention relates to derives from the medicinal plants of Compositae extract.Research shows, Herba Taraxaci has hepatic cholagogic effect.Herba Taraxaci is to the treatment of hepatopathy and take good care of effect obviously, shows stabilizing cell membrane, and protection hepatocyte is without prejudice, and scavenging free radicals, repairs impaired hepatocyte, promotes the effects such as hepatocellular regeneration.Harmful substance during energy is quick and in ethanol, and decompose in time, eliminate ethanol to the damage of liver.
The curcumin that the present invention relates to derives from the rhizome extract of some plants in Zingiberaceae, Araeceae.People from Okinawa is just accustomed to before drinking, chew several local weeds of food from ancient times, and Rhizoma Curcumae Longae is exactly one of them.It can effectively alleviate drunk and hangover phenomenon.And be once described as the royal hired dealcoholization health-preserving superfine product of Japan as tribute.Afterwards, the fashionable Japan of Rhizoma Curcumae Longae, became " the life medicine " of building body.Japanese makes earnest efforts and sincerely believes in all kinds of health beverages made of Rhizoma Curcumae Longae.Rhizoma Curcumae Longae is the Japanese native country medicinal plants of extensively planting in Hokkaido, containing a large amount of curcumin in Rhizoma Curcumae Longae, fatty acid can be suppressed to synthesize, and promotes that gallbladder is to the excretion of cholesterol, has the effect of significant protection and increasing hepatocyte activity, can also antitumor.
The present invention intends the achievement in research according to clinical practice and modern molecular biology, application molecular pharmacology principle, select the newfound natural plants antioxidation hepatoprotective activity components such as astaxanthin, be aided with traditional hepatoprotective composition such as Herba Taraxaci, curcumin, composition has the novel plant compound extract of function of protecting and nourishing liver.This compound recipe and existing liver-protecting product ratio have the following advantages: (1) has increased Haematocoocus Pluvialls extract astaxanthin newly, because of the function this enhancing antioxidation, detoxify, prevent liver cancer; (2) be main component with astaxanthin, be aided with traditional Herba Taraxaci and curcumin, make liver protecting function more comprehensively.(3) weight ratio of compound recipe is determined by scientific experiments for Sha's Buddhist ibuprofen: silymarin: curcumin component 1: 10 ~ 30: 10 ~ 40; Preferred weight ratio is 1: 15 ~ 30: 25 ~ 35; Most preferably part by weight is 1:25:30, and under this ratio, liver protecting function is stronger.
Summary of the invention:
The technical problem to be solved in the present invention, mainly overcomes the incomplete deficiency of existing liver-protecting product liver-protecting function, provides a kind of novel plant compound extract with liver protection.
The technical solution used in the present invention is:
There is a novel plant compound extract product for liver protecting function, comprise astaxanthin, Herba Taraxaci and curcumin.
Preferably, described astaxanthin is Haematocoocus Pluvialls extract.
Preferably, described Herba Taraxaci is the medicinal plants of Compositae extract.
Preferably, described curcumin is the plant extracts such as Rhizoma Curcumae Longae.
Preferably, described astaxanthin, the part by weight 1: 10 ~ 30: 10 ~ 40 of Herba Taraxaci and curcumin component.More preferably part by weight is 1: 15 ~ 30: 25 ~ 35, and most preferably part by weight is 1:25:30.
More preferably, the dosage form of described compound product is the peroral dosage forms such as tablet, hard capsule, soft capsule, Orally taken emulsion, granule.
The tablet of the novel plant compound extract of liver protecting function and hard capsule dosage form; its prescription composition comprise in the diluent such as starch, lactose, mannitol, microcrystalline Cellulose, calcium hydrogen phosphate, calcium sulfate one or more; comprise one or more in the disintegrating agents such as low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose; comprise one or more in lubricants such as replacing silicon dioxide, Pulvis Talci, magnesium stearate, the stabilizing agents such as Butylated hydroxyanisole, dibenzylatiooluene, vitamin E, citric acid can be comprised.Adhesive selects water or the aqueous alcohol solutions of polyvidone, hydroxypropyl cellulose, hydroxypropyl cellulose etc.
The soft capsule dosage form of the novel plant compound extract of liver protecting function; its content prescription composition comprise in soybean oil, Oleum Ricini, Oleum Camelliae, Oleum Arachidis hypogaeae semen, medium chain wet goods oil-based solvent one or more; one or more in poly yamanashi esters, brejs, sorbitan fatty acid ester, polyoxyethylene castor oil class surfactant can be comprised, the stabilizing agents such as Butylated hydroxyanisole, dibenzylatiooluene, vitamin E, oleic acid can be comprised.
The oil-in-water Orally taken emulsion dosage form of the novel plant compound extract of liver protecting function; oil phase in its prescription composition comprises one or more in soybean oil, Oleum Ricini, Oleum Camelliae, Oleum Arachidis hypogaeae semen, medium chain wet goods oil-based solvent; emulsifier package in prescription composition is containing one or more in poly yamanashi esters, brejs, polyoxyethylene castor oil class surfactant; the stabilizing agents such as Butylated hydroxyanisole, dibenzylatiooluene, vitamin E, oleic acid can be comprised, containing the correctives such as aspartame, orange flavor, parabens antiseptic etc.The ratio of aqueous phase and oil phase is 10:1 ~ 10:15.
The beneficial effect that the present invention has:
The effects such as the plant extract compound product that use the present invention relates to, can provide removing toxic substances to liver, antioxidation, antiinflammatory, fibrosis, anticancer, provide comprehensive protection to liver, function is strong, and toxicity is little.
The composition of plant extracts that the present invention relates to is natural plant active component.Main component astaxanthin is the star's antioxidation liver-protecting product in recent years found, have potent flavacin removing toxic substances, chronic inflammatory disease is alleviated, and liver cirrhosis prevents, the effects such as prevention of hcc.The special complementation of each hepatoprotective component function, compound recipe proportioning is scientific and reasonable, therefore has significant advantage.
The plant extract compound liver-protecting product related in the present invention is applicable to the whirl of society has the person of needs that drinks with a guest that drinks, long-term alcohol person, fatty liver crowd, chronic hepatitis crowd more, or the crowd that self liver function is not good enough.
Detailed description of the invention:
Below in conjunction with specific embodiment, the invention will be further described, but do not limit protection scope of the present invention.
Embodiment 1 novel plant compound extract is to carbon tetrachloride (CC1
4) protective effect of hepatic injury of inducing
Wistar rat is divided into 5 groups of (Normal group, CCl
4model group, composition of plant extracts experimental group).Each matched group and model group are with normal saline gavage, experimental group is with composition of plant extracts (1: 20: 20,1: 25: 30,1:50:50) the composition of plant extracts suspension oral gavage of (in astaxanthin 0.075mg/kg), every 12h gavage 2 times, continuous gavage is after 7 days, and model group and experimental group lumbar injection 30%CC14 olive oil solution (1.5ml/kg), normal group gives equivalent olive oil.
Alanine aminopherase in serum (ALT), asparate aminotransferase (AST), alkali phosphatase (ALP) is detected after 16 hours; Lesion degree is observed in hepatic tissue Hematoxylin-eosin (HE) dyeing; Xanthine oxidase and thiobarbituricacidα-method detect superoxide dismutase in liver homogenate (SOD), catalase (CAT) and malonaldehyde (MDA) respectively.
Result: compare with matched group, CCl
4the content of group serum alt, AST, ALP significantly increases (P<0.05), and HE dyeing hepatic tissue degeneration necrosis involves full lobule.With CCl
4group compares, composition of plant extracts suspension+CCl
4the content of group serum alt, AST, ALP significantly declines (P < 0.05); HE staining lesions degree is comparatively light, and degeneration necrosis is confined to IIIth district of lobules of liver; In endochylema, the raising of SOD and CAT activity, MDA level reduce (P<0.05).
Conclusion: composition of plant extracts all significantly can alleviate CCl
4the hepatic injury of induction, and effect is the strongest when the part by weight of astaxanthin, Herba Taraxaci and curcumin component is 1: 25: 30.
Embodiment 2 one kinds has the preparation of the plant extract compound oral Emulsion safeguarding liver function:
Orally taken emulsion prescription:
| ? | 1000 bottles of consumptions (g) |
| Haematocoocus Pluvialls extract (by astaxanthin) | 1 |
| Herba Taraxaci extract (by taraxacin) | 25 |
| Rhizoma Curcumae Longae extract (by curcumin) | 30 |
| Midchain oil | 300 |
| Polyoxyethylene sorbitan monoleate | 10 |
| Butylated hydroxyanisole | 0.2 |
| Aspartame | 0.2 |
| Orange flavor | 0.1 |
| Sodium benzoate | 25 |
| Water | Add to 5000ml |
Preparation method: by prescription, gets 5g polyoxyethylene sorbitan monoleate, Butylated hydroxyanisole is dissolved in midchain oil, add Haematocoocus Pluvialls extract, Herba Taraxaci extract, Rhizoma Curcumae Longae extract, and grinding evenly.Another water intaking 4500ml, adds aspartame, sodium benzoate, 5g polyoxyethylene sorbitan monoleate, orange flavor, stirs, makes dissolving.Midchain oil oil solution is added aqueous solution, puts emulsion tank, add water to 5000ml, emulsifying 15min, subpackage, to obtain final product.
Embodiment 3 one kinds has the preparation of the plant extract compound capsules agent safeguarding liver function:
Content prescription:
| ? | 1000 consumptions (g) |
| Haematocoocus Pluvialls extract (by astaxanthin) | 1 |
| Herba Taraxaci extract (by taraxacin) | 25 |
| Rhizoma Curcumae Longae extract (by curcumin) | 30 |
| Polyoxyethylene sorbitan monoleate | 2 |
| Butylated hydroxyanisole | 0.2 |
| Midchain oil | Add to 300ml |
Preparation method: by prescription, gets polyoxyethylene sorbitan monoleate, Butylated hydroxyanisole is dissolved in midchain oil 250ml, add Haematocoocus Pluvialls extract, Herba Taraxaci extract, Rhizoma Curcumae Longae extract, and grinding makes dissolving or dispersion, adds midchain oil to 300ml, and grinding evenly.Separately join gelatin solution (100 parts, gelatin, glycerol 55 parts, 120 parts, water, titanium dioxide 0.5 part) for subsequent use, under the condition of room temperature 23 ± 2 DEG C, relative humidity 40%, medicinal liquid and gelatin solution encapsulating machine make soft capsule, the heavy Contents Fill 0.3ml of every ball, at 28 ± 2 DEG C, by capsule drying 20 hours under relative humidity 40% condition, to obtain final product.
Embodiment 4 one kinds has the preparation of the plant extract compound tablet safeguarding liver function:
Tablet formulation:
| ? | 1000 consumptions (g) |
| Haematocoocus Pluvialls extract (by astaxanthin) | 1 |
| Herba Taraxaci extract (by taraxacin) | 25 |
| Rhizoma Curcumae Longae extract (by curcumin) | 30 |
| Citric acid | 1 |
| Microcrystalline Cellulose | 40 |
| Lactose | 20 |
| Low-substituted hydroxypropyl cellulose | 40 |
| 2% polyvidone 50% alcoholic solution | In right amount |
| Colloid body silicon dioxide | 1 |
| Pulvis Talci | 1 |
Preparation method: by prescription, gets Haematocoocus Pluvialls extract, adds citric acid, microcrystalline Cellulose, mixing, adds Herba Taraxaci extract, Rhizoma Curcumae Longae extract, lactose, low-substituted hydroxypropyl cellulose, mixing, add 2% polyvidone 50% alcoholic solution soft material, cross 24 nylon mesh to granulate, 60 is dry, 20 order nylon mesh granulate, add colloid body silicon dioxide, Pulvis Talci, mixing, tabletting, to obtain final product.Hardness Control at 6 ~ 11kgf, every sheet by astaxanthin, astaxanthin-containing 1mg.
Claims (8)
1. there is a novel plant compound extract product for liver protecting function, it is characterized in that: this compound product comprises astaxanthin, Herba Taraxaci and curcumin.
2. a kind of novel plant compound extract product with liver protecting function according to claim 1, is characterized in that: described astaxanthin is Haematocoocus Pluvialls extract.
3. a kind of novel plant compound extract product with liver protecting function according to claim 1, is characterized in that: described Herba Taraxaci is the medicinal plants of Compositae extract.
4. a kind of novel plant compound extract product with liver protecting function according to claim 1, is characterized in that: described curcumin is the plant extracts such as Rhizoma Curcumae Longae.
5. a kind of novel plant compound extract product with liver protecting function according to claim 1, is characterized in that: described astaxanthin, the part by weight 1: 10 ~ 30: 10 ~ 40 of Herba Taraxaci and curcumin component.
6. a kind of novel plant compound extract product with liver protecting function according to claim 5, is characterized in that: described astaxanthin, the part by weight 1: 15 ~ 30: 25 ~ 35 of Herba Taraxaci and curcumin component.
7. a kind of novel plant compound extract product with liver protecting function according to claim 6, is characterized in that: described astaxanthin, the part by weight 1:25:30 of Herba Taraxaci and curcumin component.
8. a kind of novel plant compound extract product with liver protecting function according to any one of claim 1-7, is characterized in that: the dosage form of described compound product is the peroral dosage forms such as tablet, hard capsule, soft capsule, Orally taken emulsion, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410470256.9A CN104208117A (en) | 2014-09-15 | 2014-09-15 | Plant extract compound product with function of maintaining liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410470256.9A CN104208117A (en) | 2014-09-15 | 2014-09-15 | Plant extract compound product with function of maintaining liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104208117A true CN104208117A (en) | 2014-12-17 |
Family
ID=52090290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410470256.9A Pending CN104208117A (en) | 2014-09-15 | 2014-09-15 | Plant extract compound product with function of maintaining liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208117A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074662A (en) * | 2016-08-24 | 2016-11-09 | 胡铭 | A kind of Rhizoma Curcumae Longae compositions with effects of relieving alcoholism and protecting liver |
| CN107669795A (en) * | 2017-11-02 | 2018-02-09 | 威海百合生物技术股份有限公司 | A kind of composition of chemical damage caused by mitigation alcohol |
| CN108342446A (en) * | 2018-05-02 | 2018-07-31 | 大连理工大学 | A method of promoting hepatoma cell apoptosis and inhibits hepatoma cell proliferation |
| CN110123872A (en) * | 2019-06-14 | 2019-08-16 | 南京博源医药科技有限公司 | A kind of medicament and preparation method thereof for treating hepatitis |
| CN115736107A (en) * | 2022-11-28 | 2023-03-07 | 广东海洋大学 | Application of astaxanthin in preparation of feed for repairing chicken liver injury and/or improving chicken meat yield |
| CN120168597A (en) * | 2025-05-23 | 2025-06-20 | 云南绿A生物工程有限公司 | A kind of astaxanthin composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739767A (en) * | 2005-09-06 | 2006-03-01 | 易康富生物科技(南通)有限公司 | Compound recipe capable of protecting liver and improving symptoms of hepatosis |
| AU2008231570A1 (en) * | 2007-03-28 | 2008-10-02 | Aker Biomarine Human Ingredients As | Bioeffective krill oil compositions |
| CN102389073A (en) * | 2011-11-17 | 2012-03-28 | 中国食品发酵工业研究院 | Natural plant extract formula for liver protection |
| CN103446166A (en) * | 2012-05-29 | 2013-12-18 | 上野制药株式会社 | Liver function-improving agent |
-
2014
- 2014-09-15 CN CN201410470256.9A patent/CN104208117A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739767A (en) * | 2005-09-06 | 2006-03-01 | 易康富生物科技(南通)有限公司 | Compound recipe capable of protecting liver and improving symptoms of hepatosis |
| AU2008231570A1 (en) * | 2007-03-28 | 2008-10-02 | Aker Biomarine Human Ingredients As | Bioeffective krill oil compositions |
| CN102389073A (en) * | 2011-11-17 | 2012-03-28 | 中国食品发酵工业研究院 | Natural plant extract formula for liver protection |
| CN103446166A (en) * | 2012-05-29 | 2013-12-18 | 上野制药株式会社 | Liver function-improving agent |
Non-Patent Citations (1)
| Title |
|---|
| 高彦祥等: "天然色素抗氧化性研究进展", 《食品科学》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074662A (en) * | 2016-08-24 | 2016-11-09 | 胡铭 | A kind of Rhizoma Curcumae Longae compositions with effects of relieving alcoholism and protecting liver |
| CN106074662B (en) * | 2016-08-24 | 2019-10-29 | 胡铭 | A kind of turmeric composition with effects of relieving alcoholism and protecting liver |
| CN107669795A (en) * | 2017-11-02 | 2018-02-09 | 威海百合生物技术股份有限公司 | A kind of composition of chemical damage caused by mitigation alcohol |
| CN107669795B (en) * | 2017-11-02 | 2021-02-09 | 威海百合生物技术股份有限公司 | Composition for relieving chemical liver injury caused by alcohol |
| CN108342446A (en) * | 2018-05-02 | 2018-07-31 | 大连理工大学 | A method of promoting hepatoma cell apoptosis and inhibits hepatoma cell proliferation |
| CN110123872A (en) * | 2019-06-14 | 2019-08-16 | 南京博源医药科技有限公司 | A kind of medicament and preparation method thereof for treating hepatitis |
| CN115736107A (en) * | 2022-11-28 | 2023-03-07 | 广东海洋大学 | Application of astaxanthin in preparation of feed for repairing chicken liver injury and/or improving chicken meat yield |
| CN120168597A (en) * | 2025-05-23 | 2025-06-20 | 云南绿A生物工程有限公司 | A kind of astaxanthin composition and application thereof |
| CN120168597B (en) * | 2025-05-23 | 2025-07-22 | 云南绿A生物工程有限公司 | A kind of astaxanthin composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208117A (en) | Plant extract compound product with function of maintaining liver | |
| Al Snafi | Pharmacological and therapeutic importance of a review | |
| CN103202838A (en) | Plant extract composition with liver protecting effect | |
| KR20130117660A (en) | Tocotrienol compositions | |
| Almatar et al. | A glance on medical applications of Orthosiphon stamineus and some of its oxidative compounds | |
| US20190209634A1 (en) | Herbal Nutraceutical Formulation to Reduce Oxidative Stress, Viral and Microbial Infections, and Inflammation | |
| CN104906406B (en) | A kind of natural drug composition and preparation method for preventing and treating alcoholic liver injury | |
| Gudalwar et al. | Allium sativum, a potential phytopharmacological source of natural medicine for better health | |
| JP2019528297A (en) | Subcutaneous injection preparation used for weight loss and use thereof | |
| Chiu et al. | Popular functional foods and nutraceuticals with lipid lowering activity and in relation to cardiovascular disease, dyslipidemia, and related complications: an overview | |
| CN102764408B (en) | Dealcoholic preparation | |
| Yousefi et al. | Insights to potential antihypertensive activity of berry fruits | |
| Rane et al. | Nutraceuticals as disease preventive food and immunity boosters | |
| CN102784248B (en) | Chinese medicine composition for preventing and treating alcoholic liver injury | |
| WO2020202193A1 (en) | Synergistic combination of phytoactives | |
| CN102784366A (en) | Medical composition with function of decanting and protecting liver | |
| Sumera et al. | The micronutrient combination with immune-enhancing effects | |
| Yeh et al. | Antioxidant potential of solvent partitioned extraction from aqueous extract of Gracilaria tenuistipitata | |
| KR20190040305A (en) | Subcutaneous injections for weight loss and uses thereof | |
| Hassan | Oxidative stress as a crucial factor in liver associated disorders: Potential therapeutic effect of antioxidants | |
| CN101073602B (en) | Medicinal composition for treating or improving liver function, its production and use | |
| CN105194364A (en) | Medicinal composition for local burn nursing | |
| CN103976993A (en) | Plant extract composition with liver protection function | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| Mohamed | Herbs and spices in aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |